Paraguay DINAVISA trial authorization vs registro: keep the FIH file off the commercial holder track

Sponsors still put “Paraguay” on one regulatory Gantt. That is the mistake. A first-in-human (FIH) or early feasibility study (EFS) for a medical device in Paraguay runs as a DINAVISA clinical-investigation file plus an institutional ethics vote. Putting the same device on the Paraguayan market later is a DINAVISA sanitary-registration file. Same agency name. Different petition, different importer, different success criterion.

If the board slide says “DINAVISA approved,” ask which DINAVISA. Trial authorization is not a registro sanitario. Confusing them delays first patient and later stalls commercial import.

Two files, one agency

DINAVISA (Dirección Nacional de Vigilancia Sanitaria) is Paraguay’s sanitary authority. It authorizes clinical investigations for devices used in-country. Ethics sits with the site’s Comité de Ética en Investigación, not with a Miami PowerPoint. Those are sequential gates on the trial track, not a commercial license.

For a U.S. or European MedTech team, the practical split looks like this:

• Trial file: protocol, investigator brochure, informed consent in Spanish, institutional ethics package, investigational labeling, ISO 14155 monitoring plan, and the import story for units that will only be used in the study.
• Registro file: sanitary registration for manufacture, import, storage, distribution, and promotion of a commercial device, with a Paraguayan party DINAVISA will treat as responsible for that certificate — not a PI’s clinic stamp and not a named hospital that happens to have run FIH.

Public first-in-human sites in Asunción are sites. They are not the CRO and they are not the commercial titular. Do not treat a surgeon’s name as the DINAVISA commercial file.

What FDA reviewers will ask later

If the Paraguay FIH is meant to support a U.S. IDE or marketing file, design the investigation so the evidence room can satisfy 21 CFR § 812.28 (acceptance of data from clinical investigations conducted outside the United States). That regulation expects GCP, independent ethics review, and a device comparable to the version you will put in front of FDA.

ISO 14155 is the device GCP bridge FDA has publicly recognized for foreign investigations. A clean DINAVISA investigation letter does not replace an inspectable trial master file. Keep device accountability, deviation logs, monitoring reports, and the ethics correspondence in one place from day one. Eligibility of foreign data is not a clearance prediction.

Ethics-committee median timelines on bioaccess®’s Paraguay page are in the 4–6 week band. That is ethics, not DINAVISA commercial registro, and not a promise of first-patient week. Do not put a single “Paraguay clock” on the Gantt.

Import: investigational units are not the registro SKU

A commercial DINAVISA registration number does not clear investigational kits. Do not put a cousin SKU’s registro on the airway bill “because the PI knows customs.” Name the trial importer before ethics stamps the protocol. Map every investigational model, accessory, and spare to the investigation-authorized list. Outer labels must read as investigational, with lot or serial traceability that matches the accountability log at the site.

After last patient, close investigational inventory under the trial rules. Leaving units “for the hospital” without a new sanitary path is a new regulatory event, not a courtesy.

Holder vs distributor (commercial track only)

When you later want Paraguayan market access, DINAVISA will look for a local face on the sanitary registration: renewals, variations, labeling, and tecnovigilancia. A distributor who only sells stock is not automatically that holder. If the holder relationship breaks, the registro does not quietly follow the freight forwarder — you re-file.

That commercial conversation belongs on a separate workstream from the investigation calendar. Running them as one “Paraguay regulatory” workstream is how teams discover, mid-enrollment, that nobody can import the commercial launch SKU.

One-page gate before first patient in Paraguay

Write these lines with owners and document IDs before you book site initiation:

1. Authority map. DINAVISA investigation plus institutional ethics for the study. DINAVISA registro only if a parallel commercial file is truly in scope this year.
2. Ethics + investigation sequence. Same protocol version and the same Spanish informed-consent text in both packages.
3. Investigational importer. Legal name and the document that ties the shipment to the investigation authorization — not a commercial registro number.
4. Device list. Every unit that will sit in the site accountability log, including accessories.
5. ISO 14155 file owner. Who can produce monitoring, accountability, and ethics letters within 48 hours if FDA or a notified body asks.
6. Commercial holder (optional, separate). If launch is real, name the DINAVISA titular and keep that file off the FIH critical path until first patient is locked.

Where teams burn weeks

Three patterns show up repeatedly on Paraguay device files:

• PI as importer. Naming the investigator as the consignee because “he runs the lab.” Unless that person is the licensed trial importer under the investigation authorization, sanitary inspection will not treat the airway bill as study supply.
• Registro number on investigational freight. Using a commercial DINAVISA certificate for a predicate or related model to move FIH units. The investigational article is not that registered product.
• One Spanish translation for both desks. The informed-consent and brochure language for ethics and the investigation is not the commercial IFU DINAVISA will later lock. Mixing them creates labeling debt on both tracks.

Fix the patterns on paper before translators start. Re-translation after first patient is a protocol amendment problem, not a word-processing problem.

Practical next step

This week, split the Paraguay slide into two columns: DINAVISA investigation and DINAVISA registro. If the same person owns both without two dossiers, two importers, and two success criteria, you do not have a Paraguay plan — you have a hope. bioaccess® runs FIH/EFS execution across Latin America, including Paraguay, and holds LATAM registration/IOR work as a separate market-access track; treat Paraguay the same way inside your own team.